A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

被引：0

作者：

Freedman, O. C. ^{[1
]}

Amir, E. ^{[1
]}

Dranitsaris, G. ^{[1
]}

Dowsett, M. ^{[2
]}

Cole, D. E. C. ^{[3
]}

Kahn, H. ^{[4
]}

O'Malley, F. ^{[5
]}

Verma, S. ^{[6
]}

Clemons, M. ^{[1
]}

机构：

[1] Princess Margaret Hosp, Div Hematol & Med Oncol, Toronto, ON M4X 1K9, Canada

[2] Royal Marsden Hosp, Dept Biochem, London SW3 6JJ, England

[3] Womens Coll Hosp, Dept Biochem, Toronto, ON M5S 1B2, Canada

[4] Sunnybrook Med Ctr, Dept Biochem, Toronto, ON, Canada

[5] Mt Sinai Hosp, Dept Pathol, Toronto, ON M5G 1X5, Canada

[6] Sunnybrook Med Ctr, Div Med Oncol, Toronto, ON, Canada

来源：

BREAST CANCER RESEARCH | 2009年 / 11卷

关键词：

Estradiol; Aromatase Inhibitor; Advanced Breast Cancer; Anastrozole; Exemestane;

D O I：

10.1186/bcr2316

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S20 / S20

页数：1